(HealthDay)—For patients presenting with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI), a postrandomization subgroup analysis suggests that a prasugrel-based strategy is superior to a ticagrelor-based strategy, according to a study published online June 30 in JAMA Cardiology….